Novo Nordisk’s Q2 Earnings Fall Short Amid Cooling GLP-1 Demand: What This Means for Pharma Investors
Novo Nordisk (NVO) Faces a Perfect Storm: What Investors Need to Know Now Novo Nordisk’s recent earnings report sent ripples through the market, with shares dipping pre-market after the company missed both top- and bottom-line … Read more